Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.
复制标题
DOI：
10.1038/modpathol.2012.104
复制
发表时间：
2012-11
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
PTEN(10号染色体上的磷酸酶和张力蛋白同源基因)是人类癌症中最常见的肿瘤抑制基因之一，超过三分之二的晚期/侵袭性前列腺癌患者都有PTEN基因的存在。以前的研究表明，在前列腺癌中，基因组PTEN缺失与肿瘤进展和预后不良有关。因此，我们使用嵌套病例对照研究来评估免疫组织化学PTEN在前列腺癌腺体中的表达是否与更高的复发风险有关，该研究包括451名接受根治性前列腺癌切除术的临床局部前列腺癌复发患者和451名未复发患者。复发定义为生化复发(血清前列腺特异性抗原0.2 ng/ml)或临床复发(局部复发、全身转移或前列腺癌相关死亡)。病例和对照组在病理T分期、Gleason评分、种族/民族和手术年龄方面匹配。使用条件Logistic回归估计复发的优势比和95%的可信区间，以说明匹配的因素，并根据手术年份、术前前列腺特异性抗原浓度和手术切缘状况进行调整。复发组PTEN阴性表达(16vs11%，P=0.05)和PTEN缺失(40vs31%，P=0.02)明显高于对照组。与其他男性相比，PTEN表达明显降低的男性复发风险更高(优势比=1.67；95%可信区间为1.09、2.57；P=0.02)。总之，在接受前列腺癌切除术的临床局限性前列腺癌患者中，PTEN表达降低与复发风险增加相关，与已知的临床病理因素无关。
PTEN (phosphatase and tensin homolog on chromosome 10) is one of the most frequently lost tumor suppressor genes in human cancers and it has been described in more than two-thirds of patients with advanced/aggressive prostate cancer. Previous studies suggest that, in prostate cancer, genomic PTEN loss is associated with tumor progression and poor prognosis. Thus, we evaluated whether immunohistochemical PTEN expression in prostate cancer glands was associated with higher risk of recurrence, using a nested case–control study that included 451 men who recurred and 451 men who did not recur with clinically localized prostate cancer treated by radical prostatectomy. Recurrence was defined as biochemical recurrence (serum prostate-specific antigen >0.2 ng/ml) or clinical recurrence (local recurrence, systemic metastases, or prostate cancer-related death). Cases and controls were matched on pathological T stage, Gleason score, race/ethnicity, and age at surgery. Odds ratios of recurrence and 95% confidence intervals were estimated using conditional logistic regression to account for the matching factors and to adjust for year of surgery, preoperative prostate-specific antigen concentrations, and status of surgical margins. Men who recurred had a higher proportion of PTEN negative expression (16 vs 11%, P = 0.05) and PTEN loss (40 vs 31%, P = 0.02) than controls. Men with markedly decreased PTEN staining had a higher risk of recurrence (odds ratio = 1.67; 95% confidence intervals 1.09, 2.57; P = 0.02) when compared with all other men. In summary, in patients with clinically localized prostate cancer treated by prostatectomy, decreased PTEN expression was associated with an increased risk of recurrence, independent of known clinicopathological factors.
登录
查看更多内容
影响因子：
11.2
作者：
Carracedo A;Alimonti A;Pandolfi PP
通讯作者：
Pandolfi PP
影响因子：
5.6
作者：
Chaux, Alcides;Albadine, Roula;Netto, George J.
通讯作者：
Netto, George J.
DOI：
10.1038/modpathol.2011.111
发表时间：
2011-11
期刊：
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
影响因子：
--
作者：
通讯作者：
--
影响因子：
50.3
作者：
Mulholland DJ;Tran LM;Li Y;Cai H;Morim A;Wang S;Plaisier S;Garraway IP;Huang J;Graeber TG;Wu H
通讯作者：
Wu H
影响因子：
50.3
作者：
Carver BS;Chapinski C;Wongvipat J;Hieronymus H;Chen Y;Chandarlapaty S;Arora VK;Le C;Koutcher J;Scher H;Scardino PT;Rosen N;Sawyers CL
通讯作者：
Sawyers CL